In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant patient-reported outcome, which is essential in individualized therapy planning. Prospective data on HRQoL in lower-risk MDS remain rare. We assessed HRQOL by EQ-5D questionnaire at initial diagnosis in 1690 consecutive IPSS-Low/Int-1 MDS patients from the European LeukemiaNet Registry. Impairments were compared with age- and sex-matched EuroQol Group norms. A significant proportion of MDS patients reported moderate/severe problems in the dimensions pain/discomfort (49.5%), mobility (41.0%), anxiety/depression (37.9%), and usual activities (36.1%). Limitations in mobility, self-care, usual activities, pain/discomfort, and EQ-VAS were significant...
Myelodysplastic syndromes (MDS) are a type of blood cancer that derive from ineffective hematopoiesi...
Objectives: Health-related quality of life (HRQoL) data generated by generic, preference-based instr...
Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related qual...
In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant pat...
Health-related quality of life (HRQoL) is an important goal of therapy for patients with myelodyspla...
Contains fulltext : 192212.pdf (publisher's version ) (Open Access
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia w...
Background Clinical decision-making for patients with myelodysplastic syndromes (MDS) is challenging...
Health-related quality of life (HRQOL), symptom burden and other types of patient-reported outcomes ...
Objectives To examine contemporary survival patterns in the general population of patients diagnosed...
Myelodysplastic syndromes (MDS) are in the majority of cases characterized by anemia. Both anemia an...
Health-related quality of life (HRQOL) assessment is important to facilitate decisions in the curren...
Health-related quality of life (HRQOL) and other patient-reported outcomes (PROs) are crucial for a ...
Cancer incidence increases exponentially with advancing age, cancer patients live longer than in the...
Myelodysplastic syndromes (MDS) are a type of blood cancer that derive from ineffective hematopoiesi...
Objectives: Health-related quality of life (HRQoL) data generated by generic, preference-based instr...
Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related qual...
In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant pat...
Health-related quality of life (HRQoL) is an important goal of therapy for patients with myelodyspla...
Contains fulltext : 192212.pdf (publisher's version ) (Open Access
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and blood cytopenia w...
Background Clinical decision-making for patients with myelodysplastic syndromes (MDS) is challenging...
Health-related quality of life (HRQOL), symptom burden and other types of patient-reported outcomes ...
Objectives To examine contemporary survival patterns in the general population of patients diagnosed...
Myelodysplastic syndromes (MDS) are in the majority of cases characterized by anemia. Both anemia an...
Health-related quality of life (HRQOL) assessment is important to facilitate decisions in the curren...
Health-related quality of life (HRQOL) and other patient-reported outcomes (PROs) are crucial for a ...
Cancer incidence increases exponentially with advancing age, cancer patients live longer than in the...
Myelodysplastic syndromes (MDS) are a type of blood cancer that derive from ineffective hematopoiesi...
Objectives: Health-related quality of life (HRQoL) data generated by generic, preference-based instr...
Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related qual...